Lynn Tetrault | Interim CEO |
Charlie Eidson | Director of Investor Relations |
Bill Bonello | Chief Financial Officer |
Chris Smith | Incoming Chief Executive Officer |
David Sholehvar | President, Clinical Division |
Vishal Sikri | President, Pharma Services Division and President-Inivata |
Brian Weinstein | William Blair |
Alex Nowak | Craig-Hallum |
David Westenberg | Piper Sandler |
Puneet Souda | SVB Securities |
Dan Brennan | Cowen |
Andrew Cooper | Raymond James |
Mark Massaro | BTIG |
Derik de Bruin | Bank of America |
Yuko Oku | Morgan Stanley |
David Delahunt | Goldman Sachs |
Mike Matson | Needham |
Mason Carrico | Stephens, Inc. |
Good day, ladies and gentlemen, and welcome to the NeoGenomics Second Quarter 2022 Earnings Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation. It is now my pleasure to turn the floor over to your host, Lynn Tetrault. Ma’am, the floor is yours.
Thank you, Mike, and good morning.